03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
20:11 , Sep 26, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Choroidal neovascularization (CNV); ophthalmic Mouse studies suggest a cell-permeable CAV1-based fusion peptide could help treat CNV and retinal neovascularization. In choroid and retina samples from a mouse model of CNV, levels of CAV1 were higher...
00:07 , Jun 7, 2017 |  BC Extra  |  Company News

Lung Therapeutics raises $14.3M series B round

Lung Therapeutics Inc. (Austin, Texas) raised $14.3 million in a series B round led by Bios Partners. Founding investor UT Horizon Fund also participated. Lung’s lead product LTI-01, a single-chain urokinase plasminogen activator, is in a...
07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphodiesterase 3B, cGMP-inhibited (PDE3B); caveolin 3 (CAV3)

Cardiovascular disease INDICATION: Myocardial infarction (MI) In vitro and mouse studies suggest inhibiting PDE3B could help treat MI. In a mouse model of cardiac ischemia/reperfusion injury, cardiac-specific knockout of PDE3B decreased infarct size, increased levels of cardioprotective...
07:00 , Sep 23, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Glaucoma Caveolin 1 caveolae protein 22kDa (CAV1); caveolin 2 (CAV2) Genomewide association studies identified a SNP...
07:00 , Apr 22, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Renal transplant rejection Caveolin 1 (caveolae protein 22kDa; CAV1) Studies in humans suggest that a CAV1 SNP...
07:00 , Jul 23, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis Caveolin 1...